Imipenem and Meropenem: Comparison of In Vitro Activity, Pharmacokinetics, Clinical Trials and Adverse Effects

Imipenem and Meropenem: Comparison of In Vitro Activity, Pharmacokinetics, Clinical Trials and Adverse Effects

OBJECTIVE: To compare and contrast imipenem and meropenem in terms of in vitro activity, pharmacokinetics, clinical efficacy and adverse effects.

Saved in:

Bibliographic Details
Main Authors:	George G Zhanel, Andrew E Simor, Lavern Vercaigne, Lionell Mandell, the Canadian Carbapenem Discussion Group
Format:	Article
Language:	English
Published:	Wiley 1998-01-01
Series:	Canadian Journal of Infectious Diseases
Online Access:	http://dx.doi.org/10.1155/1998/831425
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mutant Prevention Concentrations of Imipenem and Meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii
by: E. Dahdouh, et al.
Published: (2014-01-01)

Ciprofloxacin or Imipenem Use Correlates with Resistance in Pseudomonas aeruginosa
by: George G Zhanel, et al.
Published: (1998-01-01)

Mutant Prevention Concentrations of Doripenem and Meropenem Alone and in Combination with Colistin (Polymyxin E), Levofloxacin and Tobramycin in Pseudomonas aeruginosa
by: George G Zhanel, et al.
Published: (2009-01-01)

Torsade de Pointes Induced by Hypokalemia from Imipenem and Piperacillin
by: Varun Kumar, et al.
Published: (2017-01-01)

Phenotypic Detection of Metallo-β-Lactamase in Imipenem-Resistant Pseudomonas aeruginosa
by: Yalda Khosravi, et al.
Published: (2012-01-01)

Evaluating the use of meropenem in hematologic patients with febrile neutropenia
by: R.A. Stuurman, et al.
Published: (2023-10-01)

Genetic Diversity of Imipenem-Resistant Acinetobacter baumannii Infections at an Intensive Care Unit
by: Amani Alnimr, et al.
Published: (2020-01-01)

In Vitro Activities of Ertapenem and Imipenem against Clinical Extended Spectrum Beta-Lactamase-Producing Enterobacteriaceae Collected in Military Teaching Hospital Mohammed V of Rabat
by: M. Elouennass, et al.
Published: (2012-01-01)

Etodolac Single Dose Metabolic Profile Elucidation: Pharmacokinetics and Adverse Events in Healthy Volunteers
by: Karen Sánchez-Luquez, et al.
Published: (2025-01-01)

Therapeutic Drug Monitoring of Meropenem in Neonate with Necrotizing Enterocolitis: A Challenge
by: Steven De Keukeleire, et al.
Published: (2016-01-01)

Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows
by: Tushar Jain, et al.
Published: (2024-12-01)

Synergistic effect of meropenem and vancomycin antibiotics with Ecballium elaterium and Senna italica extracts
by: Lubna Abdallah, et al.
Published: (2025-01-01)

Improved Clinical Outcomes with Appropriate Meropenem De-escalation in Patients with Febrile Neutropenia
by: Tyler Luu, et al.
Published: (2024-12-01)

Systematic review and meta-analysis of colistin plus meropenem therapy for the treatment of nosocomial pneumonia
by: Hazhir Moradi, et al.
Published: (2024-12-01)

Optimization of meropenem continuous infusion based on Monte Carlo simulation integrating with degradation study.
by: Nguyen Tran Nam Tien, et al.
Published: (2024-01-01)

Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021
by: Marya D. Zilberberg, et al.
Published: (2025-01-01)

Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
by: Isabel Machuca, et al.
Published: (2024-11-01)

Concomitant Administration of Vancomycin with a High Dose of Meropenem May Cause Acute Kidney Injury
by: Yoshiro Sakai, et al.
Published: (2024-01-01)

Antistaphylococcal Efficacy of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients with Polymicrobial Infection with MSSA Bacteremia or Pneumonia
by: Laila M. Najia, et al.
Published: (2023-01-01)

Dialysate and plasma meropenem concentrations in continuous intraperitoneal regimen during peritoneal-dialysis-related peritonitis
by: Thatsaphan Srithongkul, et al.
Published: (2025-01-01)

Adsorption Characteristics of Antibiotic Meropenem on Magnetic CoFe2O4@Au Nanoparticles
by: Thi Ngoc Mai Pham, et al.
Published: (2022-01-01)

Spread of TEM, VIM, SHV, and CTX-M β-Lactamases in Imipenem-Resistant Gram-Negative Bacilli Isolated from Egyptian Hospitals
by: El sayed Hamdy Mohammed, et al.
Published: (2016-01-01)

Cross-Canada Survey of Resistance of 2747 Aerobic Blood Culture Isolates to Piperacillin/Tazobactam and Other Antibiotics
by: Kevin R Forward, et al.
Published: (1998-01-01)

In Vitro Antibacterial and Antioxidant Activities, Pharmacokinetics, and In Silico Molecular Docking Study of Phytochemicals from the Roots of Ziziphus spina-christi
by: Hadush Gebrehiwot, et al.
Published: (2024-01-01)

The Use of Spreadsheets for Pharmacokinetic Simulations
by: Joseph Chamberlain
Published: (2003-01-01)

Safety, Tolerability, and Pharmacokinetics of NIM‐1324 an Oral LANCL2 Agonist in a Randomized, Double‐Blind, Placebo‐Controlled Phase I Clinical Trial
by: Andrew Leber, et al.
Published: (2025-01-01)

In vitro and in silico Anti-diabetes mechanism of phytochemicals from Curculigo pilosa and its pharmacokinetic profiling via α-amylase inhibition
by: Damilola A. Omoboyowa, et al.
Published: (2025-06-01)

UPLC-MS/MS Method for Givinostat in Rat Plasma: Development, Validation, in vivo Pharmacokinetics Study and in vitro Metabolic Stability Research
by: Zhan R, et al.
Published: (2025-01-01)

Initial Antimicrobial Treatment of Hospital Acquired Pneumonia in Adults: A Conference Report
by: Lionel A Mandell, et al.
Published: (1993-01-01)

A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)
by: Junjie Li, et al.
Published: (2025-04-01)

Conducting clinical trials with self-collection of pharmacokinetic samples: Experience from an exploratory, phase 1, open-label trial of centanafadine SR in healthy individuals
by: Chelsea Ye, et al.
Published: (2025-02-01)

Pharmacokinetic and pharmacodynamic data analysis : concepts and applications /
by: Gabrielsson, Johan
Published: (2016)

Population Pharmacokinetics of Vancomycin in Thai Patients
by: Tunggul Adi Purwonugroho, et al.
Published: (2012-01-01)

Meropenem Continuous Infusion in a Septic Patient with Periprosthetic Infection and End-Stage Renal Disease Undergoing Prolonged Intermittent Renal Replacement Therapy
by: Assiya Kadralinova, et al.
Published: (2025-01-01)

Intravenous meropenem and intraperitoneal use of 10% aqueous extract of Schinus terebinthifolius Raddi (Anacardiaceae) in elderly rats after induction of autogenous fecal peritonitis
by: Carlos Alberto Figueiredo Filho, et al.
Published: (2025-01-01)

A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults
by: Xiaomeng Mao, et al.
Published: (2025-01-01)

Target trial emulation to evaluate the effect of immune-related adverse events on outcomes in metastatic urothelial cancer
by: Renate Pichler, et al.
Published: (2024-12-01)

Study of the Comparative Activity of Piperacillin/Tazobactam with Currently Available Antibiotics against 8206 Aerobic Isolates
by: Kevin R Forward, et al.
Published: (1997-01-01)

In Vitro Activities of Ceftobiprole and Doripenem Tested against Frequently Encountered Aerobic and Facultative Gram-Positive and Gram-Negative Bacterial Pathogens Isolated from Patients in Canadian Hospitals in 2007
by: James A Karlowsky, et al.
Published: (2009-01-01)

Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats
by: Xiaohan Cao, et al.
Published: (2014-01-01)